Navigation Links
Jubilant DraxImage And Positron Enter Into A Strategic Collaboration On The Sourcing And Supply Of Strontium-82 And Rubidium-82 Generators
Date:9/6/2012

BALTIMORE, Sept. 6, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), - is pleased to announce that Jubilant DraxImage Inc. (hereinafter "JDI"), a Jubilant Life Sciences Company, and Positron Corporation (hereinafter "Positron"), have executed a Letter of Intent pertaining to:

(a)         Positron's supply of Active Pharmaceutical Ingredient (API) grade Sr-82 for the JDI Sr-82/Rb-82 generator;

(b)      JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users (upon FDA clearance); and

(c)      Positron's lifecycle management for expired JDI Sr-82/Rb-82 generators.

The strategic alliance between JDI and Positron will facilitate the stabilization, security and growth of the industry by increasing the supply of radioisotopes and radiopharmaceuticals. The Parties expect that it will also provide considerable benefits to both Parties: Positron secures a generator supply for future sales of cardiac PET scanners and a customer for Sr-82; JDI secures a reliable supply of Sr-82, a vendor for expired generators management, and a strategic partner with a growing customer base of cardiac PET scanners installed and serviced.

Martyn Coombs, President of Jubilant DraxImage stated, "Through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), Positron positioned itself as the only private entity in the U.S. with the practical experience of servicing the Sr82/Rb82 generator lifecycle.  Their ability to provide a more stable and secure supply of API Sr-82 and management of expired Sr-82/Rb-82 generators fits well with JDI's pre-launch strategy. "

Patrick Rooney, Chief Executive Officer of Positron stated, "JDI has developed a robust Sr82/Rb82 generator and elution system. As the Sr82/Rb82 generator on the market has enjoyed tremendous growth and the merits of the technology have been validated many times over, we strongly believe that the arrival of an alternative, upon the FDA clearance of JDI's generator, will be welcomed by the cardiac PET community."

JDI and Positron expect to complete a Definitive Agreement within 3 months.

About Jubilant DraxImage Inc.:
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and markets diagnostic and therapeutic radiopharmaceuticals for the global nuclear medicine marketplace. Jubilant DraxImage Inc.'s mission is to be a leading global provider of radiopharmaceuticals and value-added enabling technologies. Products include a proprietary line of lyophilized Technetium-99m kits (MAA, MDP, DTPA and Sestamibi). Jubilant DraxImage Inc. is also a leading supplier of I-131 radiopharmaceuticals in North America, used for the diagnosis and treatment of thyroid disorder and cancer. Jubilant DraxImage Inc. products are exported worldwide, with regulatory approvals in USA, South America, parts of Europe and South Asia. More information about Jubilant DraxImage is available at www.draximage.com.

About Positron Corporation:
Positron Corporation (OTCBB:POSC) is a leading molecular imaging healthcare company vertically integrating all the segments of nuclear cardiology—providing an end-to-end solution for cardiac PET.  Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology.  Positron is redefining the industry. More information about Positron is available at www.positron.com.


'/>"/>
SOURCE Positron Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Positron Accepts Economic Incentives Offer From The City Of Gary, Indiana For $30 Million Towards 70 MeV Cyclotron Project
2. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
3. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
4. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
5. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
6. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
7. CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics
8. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
9. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
10. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
11. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... SALT LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... create efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been ... served as WEDI’s interim CEO since January 2016. As an executive leader with more ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for ... be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly ... tissue regeneration. , The novel method, developed by WPI faculty members Raymond Page, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
Breaking Biology Technology:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):